Abstract: The present disclosure relates optical imaging devices and methods useful in biological and medical imaging applications. In one embodiment, an optical imaging device includes a flexible lightguide having a first end and a second end, the output of the source of pulsed infrared radiation being optically coupled to the first end of the flexible lightguide; a lens assembly attached to and optically coupled to the second end of the flexible lightguide, the lens assembly comprising a variable-focus lens element, the a variable-focus lens element having a tunable focal length; and a photodetector coupled to the flexible lightguide to detect radiation propagating from the second end toward the first end of the flexible lightguide. The optical imaging devices and methods can be used in both confocal and multi-photon techniques.

Abstract: Aspects of the subject technology relate to systems, methods, and computer-readable media for machine learning analysis of low-frequency signal data in fracturing operations. The present technology can receive strain data associated with a monitoring well that is proximate to a treatment well. The strain data can comprise information representing a fracturing operation associated with the treatment well. Further, the present technology can convert the strain data into image data where a color scale corresponds to a degree of strain observed by a fiber optic cable deployed in the monitoring well. As follows, the present technology can provide the image data to a machine-learning model, which is configured to identify one or more features in the image data.

Abstract: A syringe stabilizing apparatus has a base and a syringe support. The syringe support is vertically disposed above the base, elevating a fluid-filled portion of an infusion set vertically above the base and orienting a delivery end of the fluid-filled portion upwardly relative to a horizontal plane to take advantage of a gravitational effect on a fluid during delivery of the fluid from the fluid-filled portion to a patient. The syringe support comprises a first retainer and a selectively actuated tube clamp. The first retainer has an opening in which a rigid portion of the infusion set is received and retained therein without further user intervention. The selectively actuated tube clamp is operatively aligned with the first retainer. A flexible tube extending from the rigid portion of the infusion set extends through the selectively actuated tube clamp.

Abstract: Aspects of the subject technology relate to systems, methods, and computer-readable media for machine learning analysis of low-frequency signal data in fracturing operations. The present technology can receive strain data associated with a monitoring well that is proximate to a treatment well. The strain data can comprise information representing a fracturing operation associated with the treatment well. Further, the present technology can convert the strain data into image data where a color scale corresponds to a degree of strain observed by a fiber optic cable deployed in the monitoring well. As follows, the present technology can provide the image data to a machine-learning model, which is configured to identify one or more features in the image data.

Abstract: A system may include a processor to receive vehicle data from a vehicle system at a first location and communicate the data to a second location. The processor may integrate the data into a database of diagnostic data at the second location and identify a diagnostic code that indicates an expected operation of the vehicle system or an unexpected operation. The processor may determine a maintenance operation based on the diagnostic code. A method may include receiving vehicle data from a vehicle system at a first location and communicating the vehicle data to a second location. The method may include integrating the vehicle data into a database of first diagnostic data and identifying a diagnostic code that indicates whether the vehicle data represents an expected operation of the vehicle system or an unexpected operation of the vehicle system. The method may include determining a maintenance operation based on the code.

Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Abstract: A method can be used to determine multi-phase measurements of fluid flowing with respect to a wellbore. Signals can be received, and the signals can be emitted by each variable frequency acoustic emitter of a set of variable frequency acoustic emitters positioned spaced apart in a sensing transducer that is in an interior of a wellbore. The received signals can be converted into a flow rate of each of a set of different fluid phases of a fluid in the wellbore. The multi-phase measurements of the fluid can be determined using the converted flow rate.

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10, Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Abstract: A plating system for attaching a pair of tie plates to a wooden railroad tie with screw spikes such that the tie plates are aligned and in gauge. A predrilling system is used to predrill holes in the appropriate position on the railroad tie according to the line end of the tie prior to loading the tie into the plating system. The plating system clamps the railroad tie in registration according to the line end of the tie, and holds the tie plates in the appropriate position while a pair of hydraulic screw-presses turn screw spikes to fasten the tie plates to the railroad tie in gauge, centered and aligned on the railroad tie.

Abstract: There is provided a compound of formula (I), wherein L1 to L3?, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.

Abstract: Conventional internet routing is handled using routing protocols such as the Border Gateway Protocol (BGP). However, simple BGP does not account for latency, packet loss, or cost. To address this problem, smart routing systems that route traffic fast and in a cost-effective manner are implemented. In one approach, smart routing systems measure, compare, and analyze round-trip latencies and other metrics between a customer premises and one or more endpoints. Optimal inbound and outbound transit providers are selected for each endpoint based on these measurements. Other smart routing systems collect and analyze Real User Monitoring (RUM) data to predict latency performance of different content origins for serving data to a particular client based on the client's IP address and the content origins' IP addresses, which are ranked by performance.

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Abstract: A plating system for attaching a pair of tie plates to a wooden railroad tie with screw spikes such that the tie plates are aligned and in gauge. A predrilling system is used to predrill holes in the appropriate position on the railroad tie according to the line end of the tie prior to loading the tie into the plating system. The plating system clamps the railroad tie in registration according to the line end of the tie, and holds the tie plates in the appropriate position while a pair of hydraulic screw-presses turn screw spikes to fasten the tie plates to the railroad tie in gauge, centered and aligned on the railroad tie.